secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-01-11T23:59:59+00:00
Accession:  0001654954-22-000342
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO
--------------------------------------------------------------------------------

- Andrew A. Dahl terminated as President and CEO on January 4, 2022.
- John B. Payne, previously Chairman, appointed President and CEO effective January 7, 2022.
- Payne founded Compassion-First Pet Hospitals; served as President and CEO until 2020.
- Payne removed from Compensation and Audit Committees; Christopher Maggiore appointed.
- Company highlights 2021 progress including Nasdaq uplisting; expects seamless transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-000342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer